Fig. 8

Effect of treatment on CRP and clinical outcome in the CIA study in rhesus monkeys. Curves depict results from individual animals. Acute responders and animals with neutralizing ADAs are indicated in black. Colored lines indicate animals with active drug levels throughout the entire study. Animals with high discomfort scores had to be euthanized during the study period. (a-c) Development of acute phase response as measured by CRP production. (d-f) Clinical score was calculated based on clinical signs, soft tissue swelling, body temperature, and body weight. Clinical score was monitored twice weekly. (a, d) Placebo; (b, e) 7.5 mg/kg ALX-0061; (c, f) 10 mg/kg TCZ ADA: anti-drug antibodies; CIA: collagen-induced arthritis; CRP: C-reactive protein; TCZ: tocilizumab